Cutia Therapeutics
HKSE 2487.HK
Cutia Therapeutics Free Cash Flow for the year ending December 31, 2023: USD -61.58 M
Cutia Therapeutics Free Cash Flow is USD -61.58 M for the year ending December 31, 2023, a -14.39% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
-
Cutia Therapeutics Free Cash Flow for the year ending December 31, 2022 was USD -53.83 M, a -84.14% change year over year.
-
Cutia Therapeutics Free Cash Flow for the year ending December 31, 2021 was USD -29.24 M.
Key data
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
Market news
Loading...
HKSE: 2487.HK
| CEO | Ms. Lele Zhang |
| IPO Date | June 12, 2023 |
| Location | China |
| Headquarters | Huanzhi Building |
| Employees | 360 |
| Sector | Health Care |
| Industries | |
Description
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email